Slide 1: Third Quarter 2017 Earnings Teleconference
Third Quarter 2017 Earnings Teleconference October 31, 2017
Slide 2: Introduction
Introduction Chuck Triano Senior Vice President, Investor Relations Third Quarter 2017 Earnings
Slide 3: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Our discussions during this conference call will include forward-looking statements about, among other things, our anticipated future operating and financial performance, business plans and prospects, in-line products and product candid
Slide 4: Opening Remarks
Opening Remarks Ian Read Chairman and Chief Executive Officer Third Quarter 2017 Earnings
Slide 5: CEO Perspectives
CEO Perspectives Another strong quarter for Pfizer Innovative Health driven by key brands Ibrance: we remain confident in continued growth potential despite increasing competition Xtandi: continued sequential revenue growth; positive PROSPER data in non-metastatic Xeljanz: fastest-growing ad
Slide 6: Financial Review
Financial Review Frank D’Amelio Executive Vice President & Chief Financial Officer Third Quarter 2017 Earnings
Slide 7: Income Statement Highlights
Income Statement Highlights ($ Millions, Except Per Share Amounts and Percentages) Third Quarter 2017 2016 Change Revenues $13,168 $13,045 1% Reported Net Income(1) 2,840 1,355 110% Reported Diluted EPS(1) 0.47 0.22 113% Adjusted Income(2) 4,059 3,761 8% Adjusted Diluted EPS(2) 0.67 0.61 10% Reporte
Slide 8: Impact of Foreign Exchange on Revenues and Select Adjusted Income Components
Impact of Foreign Exchange on Revenues and Select Adjusted Income(1) Components ($ Millions, Except Percentages) Favorable / (Unfavorable) Third Quarter 2017 2016 FX Impact Revenues $13,168 $13,045 ($54) —% Adjusted Cost of Sales(1) 2,699 2,957 2 —% COS as a Percentage of Revenues 20.5% 22.7% (0.1 p
Slide 9: 2017 Financial Guidance
2017 Financial Guidance(1)(2) $52.4 to $53.1 billion Revenues (previously $52.0 to $54.0 billion) 20.0% to 20.5% Adjusted Cost of Sales(3) as a Percentage of Revenues (previously 20.0% to 21.0%) $14.0 to $14.5 billion Adjusted SI&A Expenses(3) (previously $13.7 to $14.7 billion) $7.5 to $7.8 billion
Slide 10: Key Takeaways
Key Takeaways Delivered strong Q3 2017 financial results, with 4% operational revenue growth versus Q3 2016, excluding HSP Infusion Systems from both periods, led by strong growth from Ibrance, Eliquis and Xeljanz, as well as contributions from newly-acquired products including Xtandi Narrowed certa
Slide 11: Third Quarter 2017 Earnings Teleconference Q&A Session
Third Quarter 2017 Earnings Teleconference Q&A Session October 31, 2017